Published in
American Society of Tropical Medicine and Hygiene, American Journal of Tropical Medicine and Hygiene, 4(91), p. 833-843, 2014
Links
- ORCID
- ORCID
- ORCID
- American Society of Tropical Medicine and Hygiene
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [fieldresearch.msf.org] | PDF
- [espace.cdu.edu.au] | PDF
- [europepmc.org] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [researchonline.lshtm.ac.uk] | PDF
Tools
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine
,
Nahla B. Gadalla,
Davis Tm,
Christian Nsanzabana,
Ric N. Price,
Clarissa Moriera,
A. Martensson,
Andreas Mårtensson,
Philip J. Rosenthal,
Price Rn,
Grant Dorsey
and other authors.
Full text: Download
Abstract
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genes are associated with decreased sensitivity to amodiaquine and lumefantrine, but effects of these polymorphisms on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients were analyzed to assess relationships between parasite polymorphisms in pfcrt and pfmdr1 and clinically relevant outcomes after treatment with AL or ASAQ. Presence of the pfmdr1 gene N86 (adjusted hazards ratio = 4.74, 95% confidence interval = 2.29 – 9.78, P